Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Laura J. Fischer, Stevan G. Severtson, Marie C. Gurrola, Janetta L. Iwanicki, Jody L. Green & Richard C. Dart. (2022) Changes in Hydrocodone Misuse Exposures Reported to U.S. Poison Centers Following Rescheduling in 2014. Substance Use & Misuse 57:7, pages 1097-1103.
Read now
Read now
Alice Wu, Christine Phan, Kim Chi Nguyen, Melvin Quindoy, Justin Lewis & Dorie E. Apollonio. (2021) Trends in hydrocodone combination product exposures reported to California Poison Control System (CPCS) following DEA rescheduling. Clinical Toxicology 59:4, pages 313-319.
Read now
Read now
Matthew L. Harrison & Thomas L. Walsh. (2019) The effect of a more strict 2014 DEA schedule designation for hydrocodone products on opioid prescription rates in the United States. Clinical Toxicology 57:11, pages 1064-1072.
Read now
Read now
Brian Patrick Murray, Joseph E. Carpenter, Camille A. Dunkley, Tim P. Moran, Musa Alfaifi, Waleed S. Alsukaiti & Ziad Kazzi. (2019) Seizures in tramadol overdoses reported in the ToxIC registry: predisposing factors and the role of naloxone. Clinical Toxicology 57:8, pages 692-696.
Read now
Read now
Christie Sun, Kathryn A. Hollenbach & F. L. Cantrell. (2018) Trends in carisoprodol abuse and misuse after regulatory scheduling: a retrospective review of California poison control calls from 2008 to 2015. Clinical Toxicology 56:7, pages 653-655.
Read now
Read now
Steven A. Seifert. (2017) Clinical toxicology: past and future. Clinical Toxicology 55:5, pages 311-312.
Read now
Read now
Articles from other publishers (19)
Elizabeth Harris, Michael Harms, Dazhe Cao, Courtney Prestwood, Lister DeBinya, Kurt Kleinschmidt, Amy Young, Srishti Saha, Jody Rule, Kristin Alvarez, Sandeep R. Das & William M. Lee. (2023) Declining rates of opioid/acetaminophen combination product overdose: 2011–2020. Hepatology Communications 7:4.
Crossref
Crossref
Katherine McLean. (2022) Policies in Need of a Problem? A Qualitative Study of Medical and Nonmedical Opioid Use among College Student-Athletes in the United States. Social Sciences 11:12, pages 586.
Crossref
Crossref
Zoe A Karavolis, Andrew B Su & Alyssa M Peckham. (2022) State-level response to gabapentin misuse in the United States: Implications and future direction. American Journal of Health-System Pharmacy 79:9, pages e143-e148.
Crossref
Crossref
Milly Bishop, Jennifer L. Schumann, Dimitri Gerostamoulos & Anselm Wong. (2021) The impact of codeine upscheduling on overdoses, Emergency Department presentations and mortality in Victoria, Australia. Drug and Alcohol Dependence 226, pages 108837.
Crossref
Crossref
Rachel A. Elphinston, Jason P. Connor, Dominique de Andrade, Linda Hipper, Chris Freeman, Gary Chan & Michele Sterling. (2021) Impact of a policy change restricting access to codeine on prescription opioid-related emergency department presentations: an interrupted time series analysis. Pain 162:4, pages 1095-1103.
Crossref
Crossref
Silken A. Usmani, Josef Hollmann, Amie Goodin, Juan M. Hincapie-Castillo, Lauren E. Adkins, Natalie Ourhaan, Razanne Oueini, Hemita Bhagwandass, Taylor Easey & Scott Martin Vouri. (2021) Effects of hydrocodone rescheduling on opioid use outcomes: A systematic review. Journal of the American Pharmacists Association 61:2, pages e20-e44.
Crossref
Crossref
Rose Cairns, Andrea L. Schaffer, Jared A. Brown, Sallie‐Anne Pearson & Nicholas A. Buckley. (2019) Codeine use and harms in Australia: evaluating the effects of re‐scheduling. Addiction 115:3, pages 451-459.
Crossref
Crossref
Brian L. Winbigler, Michael G. O’Neil, Jeremy Crain, A. Shaun Rowe & Katherine A. Ryan. (2020) Rescheduling hydrocodone combination products: Impact on patients receiving long-term HCP therapy in a large chain pharmacy—A statewide assessment. Journal of the American Pharmacists Association 60:2, pages 374-378.
Crossref
Crossref
Ebuwa O. Ighodaro, Kenneth L. McCall, Daniel Y. Chung, Stephanie D. Nichols & Brian J. Piper. (2019) Dynamic changes in prescription opioids from 2006 to 2017 in Texas. PeerJ 7, pages e8108.
Crossref
Crossref
Cormac Kennedy, Edel Duggan, Kathleen Bennett & David J. Williams. (2019) Rates of reported codeine-related poisonings and codeine prescribing following new national guidance in Ireland. Pharmacoepidemiology and Drug Safety 28:1, pages 106-111.
Crossref
Crossref
Irene B. Murimi, Hsien-Yen Chang, Mark Bicket, Christopher M. Jones & G. Caleb Alexander. (2019) Using trajectory models to assess the effect of hydrocodone upscheduling among chronic hydrocodone users. Pharmacoepidemiology and Drug Safety 28:1, pages 70-79.
Crossref
Crossref
Yong‐Fang Kuo, Mukaila A. Raji, Victor Liaw, Jacques Baillargeon & James S. Goodwin. (2018) Opioid Prescriptions in Older Medicare Beneficiaries After the 2014 Federal Rescheduling of Hydrocodone Products. Journal of the American Geriatrics Society 66:5, pages 945-953.
Crossref
Crossref
Mukaila A. Raji, Yong-Fang Kuo, Deepak Adhikari, Jacques Baillargeon & James S. Goodwin. (2018) Decline in opioid prescribing after federal rescheduling of hydrocodone products. Pharmacoepidemiology and Drug Safety 27:5, pages 513-519.
Crossref
Crossref
Benedikt Fischer, Lenka Vojtila & Paul Kurdyak. (2017) ‘Delisting’ OxyContin® to reduce prescription opioid-related harms in Ontario (Canada)-gauging effects 5 years later. Pharmacoepidemiology and Drug Safety 26:9, pages 1040-1043.
Crossref
Crossref
Stephanie TranPavel LavitasKaren StevensBonnie C. GreenwoodKaren ClementsCaroline J. AlperKimberly LenzMylissa PriceTasmina HyderyJennifer L. ArnoldMito TakeshitaRachel BaconJustin P. PeristerePaul L. Jeffrey. (2017) The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population. Journal of Managed Care & Specialty Pharmacy 23:5, pages 532-539.
Crossref
Crossref
Marc L. Fleming, Larry Driver, Sujit S. Sansgiry, Susan M. Abughosh, Matthew Wanat, Ruta V. Sawant, Erin Ferries, Kathleen Reeve & Knox H. Todd. (2017) Physicians' intention to prescribe hydrocodone combination products after rescheduling: A theory of reasoned action approach. Research in Social and Administrative Pharmacy 13:3, pages 503-512.
Crossref
Crossref
Tyler J. Varisco, Motolani E. Ogunsanya, Jamie C. Barner & Marc L. Fleming. (2017) Pharmacists’ perceptions regarding the impact of hydrocodone rescheduling on prescription volume, workflow management, and patient outcomes. Journal of the American Pharmacists Association 57:2, pages S51-S62.
Crossref
Crossref
Elizabeth C. Oehler, Rachel L. Day, David B. Robinson & Lawrence H. Brown. (2016) Has the rescheduling of hydrocodone changed ED prescribing practices?. The American Journal of Emergency Medicine 34:12, pages 2388-2391.
Crossref
Crossref
Andreas Kimergård, Paolo Deluca, Peter Hindersson & Torben Breindahl. (2016) How Resistant to Tampering are Codeine Containing Analgesics on the Market? Assessing the Potential for Opioid Extraction. Pain and Therapy 5:2, pages 187-201.
Crossref
Crossref